These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Clinical efficacy of flosequinan in heart failure. Cowley AJ. Am Heart J; 1991 Mar; 121(3 Pt 1):983-8. PubMed ID: 2000777 [Abstract] [Full Text] [Related]
25. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure. Markus H, Cowley AJ. Eur J Clin Pharmacol; 1991 Mar; 40(6):535-8. PubMed ID: 1884731 [Abstract] [Full Text] [Related]
26. Flosequinan in chronic heart failure: how is exercise capacity improved? Banning AP, Ramsey MW, Jones EA, Evans W, Carolan G, Jones CH, Henderson AH. Eur J Clin Pharmacol; 1996 Mar; 51(2):133-8. PubMed ID: 8911877 [Abstract] [Full Text] [Related]
28. A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity in chronic congestive heart failure. Motro M, Freimark D, Feinberg MS, Wynne RD, King C, Schneeweiss A. Int J Clin Pharmacol Res; 1993 Mar; 13(3):143-9. PubMed ID: 8225697 [Abstract] [Full Text] [Related]
33. Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study. Leier CV, Lima JJ, Meiler SE, Unverferth DV. Am Heart J; 1988 May; 115(5):1051-9. PubMed ID: 2966546 [Abstract] [Full Text] [Related]
34. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA. J Am Coll Cardiol; 1993 Jul; 22(1):65-72. PubMed ID: 8509565 [Abstract] [Full Text] [Related]
35. A preliminary report of the effects of orally administered enoximone on regional hemodynamics in congestive heart failure. Leier CV, Meiler SE, Matthews S, Unverferth DV. Am J Cardiol; 1987 Aug 14; 60(5):27C-30C. PubMed ID: 2956864 [Abstract] [Full Text] [Related]
36. Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart. Yano M, Kohno M, Yamamoto T, Hisaoka T, Tanigawa T, Ono K, Lee B, Konishi M, Matsuzaki M. J Cardiovasc Pharmacol; 1998 Sep 14; 32(3):466-70. PubMed ID: 9733361 [Abstract] [Full Text] [Related]
37. Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure. Riegger GA, Kahles H, Wagner A, Kromer EP, Elsner D, Kochsiek K. Cardiovasc Drugs Ther; 1990 Oct 14; 4(5):1395-402. PubMed ID: 1980598 [Abstract] [Full Text] [Related]
39. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration. Binkley PF, Nunziata E, Cody RJ. Am Heart J; 1994 Dec 14; 128(6 Pt 1):1147-56. PubMed ID: 7985595 [Abstract] [Full Text] [Related]